Screener
ImmunityBio, Inc. IBRX Free cash flow margin
Free cash flow margin at other companies
Other financials
Where this comes from
Calculated from ImmunityBio, Inc.’s reported figures.
Based on trailing twelve months.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
FAQ
- What is ImmunityBio, Inc.'s free cash flow margin?
- ImmunityBio, Inc. (IBRX) reported free cash flow margin of -212% in Q1 2026.
- How has ImmunityBio, Inc.'s free cash flow margin changed year-over-year?
- ImmunityBio, Inc.'s free cash flow margin increased by 82.4% year-over-year, from -1,207.2% to -212%.
- What is the long-term trend for ImmunityBio, Inc.'s free cash flow margin?
- Over 5 years (2020 to 2025), ImmunityBio, Inc.'s free cash flow margin has grown at a -58.6% compound annual growth rate (CAGR), from -22,431.2% to -272.6%.
- What does free cash flow margin mean?
- Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.
Ask your AI about ImmunityBio, Inc.'s free cash flow margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude